Why the study?
Atorvastatin has reported cardioprotective effects, but the mechanism by which it attenuates cardiac hypertrophy and inhibits cardiac failure remains unclear.
Does atorvastatin reduce cardiac hypertrophy and cardiomyocyte apoptosis in preclinical models of hypertrophy?
Does atorvastatin reduce cardiac hypertrophy and cardiomyocyte apoptosis in preclinical models of hypertrophy?
Atorvastatin attenuates cardiac hypertrophy and apoptosis through the AMPK/miR-143-3p/Bcl2 axis, providing a molecular mechanism for its cardioprotective effects in heart failure models.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in rat TAC model; leaves open clinical translation to human hypertrophy or heart failure.
Atorvastatin is employed as a lipid lowering agent and its heart protective effect has been recently reported as well. However, the mechanism of atorvastatin in attenuating cardiac hypertrophy and inhibiting cardiac failure is unclear. In our study, cardiac hypertrophy was induced in rats using transverse aortic constriction (TAC) method and in cardiomyocytes using angiotensin II (Ang II). Atorvastatin significantly suppressed TAC-induced heart weight increase and cardiomyocytes apoptosis in rats. At a molecular level, we found that miR-143-3p was significantly up-regulated, and the up-regulation could be inhibited by atorvastatin via activating AMPK pathway. Furthermore, it was validated that Bcl2 was one of the target genes of miR-143-3p. Taken together, the data indicated that miR-143-3p aggravated cardiac hypertrophy by inducing cardiomyocytes apoptosis through inhibiting Bcl2 expression. This study demonstrated the effects of atorvastatin in attenuating cardiac hypertrophy and inhibiting cardiac failure, which is depending on Bcl2 expression via miR-143-3p inhibition by AMPK activation.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: